Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
View Patent ↗The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
1. A method of treating or slowing the development of cachexia, weakness, fatigue, and/or fever in a patient diagnosed with an IL-6 associated disorder, comprising administering to the patient an anti-IL-6 antibody or an IL-6 binding antibody fragment, wherein the variable light chain of said antibody or IL-6 binding antibody fragment comprises the CDR 1 sequence of SEQ ID NO: 4, the CDR 2 sequence of SEQ ID NO: 5, and the CDR 3 sequence of SEQ ID NO: 6, and the variable heavy chain of said antibody comprises the CDR 1 sequence of SEQ ID NO: 7, the CDR 2 sequence of SEQ ID NO: 8 or SEQ ID NO:120, and the CDR 3 sequence of SEQ ID NO: 9, and whereby the patient's cachexia, weakness, fatigue, and/or fever is improved, and monitoring the patient to assess cachexia, weakness, fatigue, and/or fever.
2. A method of treating or slowing the development of cachexia, weakness, fatigue, and/or fever in a patient diagnosed with an IL-6 associated disorder, comprising administering to the patient an anti-IL-6 antibody or an IL-6 binding antibody fragment, wherein said antibody comprises the variable light chain polypeptide of SEQ ID NO: 18 or 19, and the variable heavy chain polypeptide of SEQ ID NO:20, and whereby the patient's cachexia, weakness, fatigue, and/or fever is improved, and monitoring the patient to assess cachexia, weakness, fatigue, and/or fever.
3. The method of claim 2 wherein the variable light chain polypeptide is SEQ ID NO:19.
4. A method of treating or slowing the development of cachexia, weakness, fatigue, and/or fever in a patient diagnosed with an IL-6 associated disorder, comprising administering to the patient an anti-IL-6 antibody or IL-6 binding antibody fragment, wherein said antibody or antibody fragment comprises a variable light and heavy chain polypeptide which is at least 90% identical to the variable light or variable heavy chain polypeptides contained in SEQ ID NOs: 18 or 19 and 20 with the proviso that the CDRs in said antibody fragment comprise CDR 1 sequence of SEQ ID NO: 4, the CDR 2 sequence of SEQ ID NO: 5, and the CDR 3 sequence of SEQ ID NO: 6 and the variable heavy chain of said antibody comprises the CDR 1 sequence of SES ID NO: 7, the CDR 2 sequence of SEQ ID NO: 8 or SEQ ID NO: 120, and the CDR 3 sequence of SEQ ID NO: 9, respectively and whereby the patient's cachexia, weakness, fatigue, and/or fever is improved, and monitoring the patient to assess cachexia, weakness, fatigue, and/or fever.
5. The method of claim 4 , wherein said antibody or antibody fragment comprises a variable light and heavy chain polypeptide which is at least 95% identical to the variable light or variable heavy chain polypeptides contained in SEQ ID NOs: 18 or 19 and 20, respectively.
6. The method of claim 4 , wherein said antibody comprises a variable light and heavy chain polypeptide which is at least 98% identical to the variable light or variable heavy chain polypeptides contained in SEQ ID NOs: 18 or 19 and 20, respectively.
7. The method of claim 4 , wherein said antibody comprises a variable light and heavy chain polypeptide which is at least 99% identical to the variable light or variable heavy chain polypeptides contained in SEQ ID NOs: 18 or 19 and 20, respectively.
8. The method of any one of claims 1 , 2 or 4 wherein the anti-IL-6 antibody is an intact antibody.
9. The method of any one of claims 1 , 2 or 4 wherein the anti-IL-6 antibody is an antibody fragment.
10. The method of any one of claims 1 , 2 or 4 wherein the anti-IL-6 antibody or fragment is non-glycosylated.
11. The method of any one of claims 1 , 2 or 4 wherein the anti-IL-6 antibody comprises a human constant domain.
12. The method of any one of claims 1 , 2 or 4 wherein the anti-IL-6 antibody comprises a human gamma 1 constant domain.
13. The method of +-any one of claims 1 , 2 or 4 wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency at most once per period of approximately four weeks.
14. The method of claim 2 wherein the anti-IL-6 antibody is an intact antibody comprising human gamma 1 constant domains and has an elimination half-life of at least about 22 days.
15. The method of any one of claims 1 , 2 or 4 , further comprising administration of another antagonist of a cachexia-associated factor, weakness-associated factor, fatigue-associated factor, and/or fever-associated factor, selected from tumor necrosis factor-alpha, Interferon gamma, Interleukin 1 alpha, Interleukin 1 beta, Interleukin 6, proteolysis inducing factor, leukemia-inhibitory factor, or an combination thereof.
16. The method of any one of claims 1 , 2 or 4 , wherein the patient, prior to undergoing said antibody or anti fragment administration is selected as a candidate for said treatment method by: measuring the patient's body weight prior to administration of the anti-IL-6 antibody, and administering the anti-IL-6 antibody or antibody fragment if the patient's weight has declined by greater than approximately 5% within approximately 30 days, or if the patient's lean body mass index is less than about 17 kg/m 2 (male patient) or less than about 14 kg/m 2 (female patient).
17. The method of any one of claims 1 , 2 or 4 , wherein the patient, prior to undergoing said antibody or antibody fragment administration is selected as a candidate for said treatment method by: measuring the patient's muscular strength prior to administration of the anti-IL-6 antibody, and administering the anti-IL-6 antibody or antibody fragment if the patient's muscular strength has declined by greater than approximately 20% within approximately 30 days.
18. The method of claims 1 , 2 or 4 wherein the variable heavy chain CDR 2 is SEQ ID NO: 120.
19. The method of any one of claims 1 , 2 or 4 wherein said antibody or antibody fragment is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient, and said composition is selected from a solution, a microemulsion, and a liposomal formulation.
20. The method of any one of claims 1 , 2 or 4 , wherein the antibody or antibody fragment is administered intravenously, intraperitoneally, intramuscularly, or subcutaneously.
21. The method of any one of claims 1 , 2 or 4 wherein the IL-6 associated disorder is a cancer.
22. A method of treating or slowing the development of cachexia, weakness, fatigue, and/or fever in a patient diagnosed with an IL-6 associated disorder, comprising administering to the patient an anti-IL-6 antibody comprising the variable heavy and light chain sequences in SEQ ID NO:19 and 20 and human IgG1 constant domains in an amount effective to treat or slow the development of cachexia, weakness, fatigue, and/or fever in said patient.
23. A method of treating or slowing the development of cachexia, weakness, fatigue, and/or fever in a patient diagnosed with an IL-6 associated disorder, comprising administering to the patient an anti-IL-6 antibody comprising the variable heavy and light chain sequences in SEQ ID NO:18 and 20 and human IgG1 constant domains in an amount effective to treat or slow the development of cachexia, weakness, fatigue, and/or fever in said patient.